期刊文献+

放射性核素骨显像联合PSA、FPSA检测对前列腺癌骨转移诊断的临床意义 被引量:2

下载PDF
导出
摘要 目的:探讨核素骨显像与前列腺特异性抗原(PSA和FPSA)对前列腺癌骨转移随访的临床意义。方法:对87例前列腺癌患者静脉注射^99Tc^m-MDP925~1110MBq行SPECT全身骨显像和PSA、FPSA的检测,观察全身骨骼放射性分布情况并与实验室检查对比分析。结果:骨显像发现54例骨转移瘤,阳性率62.1%。在接受2~6次骨显像随访的前列腺癌患者中,第1、2、3次被确诊为骨转移癌分别为28例(32.2%)、14例(16.1%)、9例(10.4%);第4~6次被确诊骨转移癌各有1例(1.1%)。前列腺癌骨转移组的PSA和FPSA均明显高于非骨转移组、治疗随访组及对照组,差异均有统计学意义(P〈0.001)。结论:前列腺癌在行骨显像随访时,联合检测PSA、FPSA对前列腺癌骨转移的预后评估有互补作用。
作者 黄红 周仲佑
出处 《广东医学院学报》 2006年第5期471-472,共2页 Journal of Guangdong Medical College
  • 相关文献

参考文献6

二级参考文献12

  • 1韩伟明.-[J].日用化学工业,1987,(3):31-31.
  • 2姜义娟.-[J].日用化学工业,1986,(3):27-27.
  • 3Partin A W, Kattan M W, Subong E N, et al.Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update[J].JAMA.1997,277:1445-1451.
  • 4Birtle A J, Freeman A, Masters J R, et al.Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen(PSA) levels<10μg/L: the ""PSA negative"" patients[J].Cancer, 2003,98(11):2362-2367.
  • 5Miller D C, Hafez K S, Stewart A, et al.Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base[J].Cancer, 2003,98(6):1169-1178.
  • 6Hermanek P, Sobin L H.Urological tumors: prostate[A].In:International union against cancer(UICC) TNM classification of malignant tumors[C].4thed.New York: Springer Verlag,1992.141-144.
  • 7Miller P D, Eardley I, Kirby R S, et al.Prostate-specific antigen and bone scan correlateion in the staging and monitoring of patients with prostatic cancer[J].Br J Urol, 1992,70:295-298.
  • 8邓守真,核技术,1993年,16卷,660页
  • 9谷现恩,现代前列腺疾病,1997年,118页
  • 10O′Donoghue J M, Rogers E, Grimes H, et al.A reappraisal of serial isotope bone scans in prostate cancer[J].Br J Radiol, 1993,66(788):672-676.

共引文献34

同被引文献10

  • 1陈海蛟,邵振华,张立,张永康.放射性核素骨显像对内分泌治疗前列腺癌疗效的观察[J].复旦学报(医学版),2005,32(3):349-351. 被引量:4
  • 2朱一平,叶定伟.高危前列腺癌的治疗进展[J].国际泌尿系统杂志,2006,26(5):602-606. 被引量:2
  • 3毛祺琦,郑祥毅,谢立平.低PSA前列腺癌的研究进展[J].国际泌尿系统杂志,2006,26(5):637-640. 被引量:2
  • 4Yahara J, Noguchi M, Noda S. Quantitative evaluation of hone metastases in patients with advanced prostate cancer during systemic treatment [J ]. BJU Int, 2003 Sep, 92 (4) : 379.
  • 5Chybowski F M. Predicting radionuelide bone scan findings in patients with newly diagnosed, untreated prostate eaneer: prostate speclfic antigen is superior to all other clinical pararneters[J]. J Urol, 1991, 145: 313.
  • 6Leo M E. Prostate-specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status[J]. J Urol, 1991, 145: 802.
  • 7Freitas. The clinical utility of Prostate-specific antigen and bone scintigraphy in prostate eaneer[J]. J Nuel Med, 1991, 32 : 1387.
  • 8Sanz G, Robles J, Gimenez M, et al. Positron emission tomography with 18 fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer[J]. BJU Int, 1999, 84 (9) : 1028.
  • 9Marcel S, Aeilko Z, Jaap Z, et al. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone sclntigram[J ]. Eur J Nud Med, 1997, 24: 1215.
  • 10胡玲美,胡晓芳,王洪军,王继群.前列腺特异性抗原在前列腺癌诊断中的应用研究[J].细胞生物学杂志,2003,25(1):14-17. 被引量:1

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部